BioE Holdings Inks an Exclusive License Agreement with NCI for BK and JC Polyomavirus Vaccines

Hyderabad (India), October 25, 2019: BioE Holdings Inc., a subsidiary of Biological E. Limited, has entered into an exclusive license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, in the United States for Virus-like Particle (VLP) Polyomavirus Vaccine(s) for the prevention / treatment of BK Polyomavirus (BKV) and/or JCV associated diseases in organ/kidney transplantation, bone marrow transplantation, and Progressive Multifocal Leukoencephalopathy (PML).

The technology was developed in the laboratory of Dr. Christopher B. Buck at NCI, which is engaged in Polyomavirus research, which includes evaluation of mechanisms of viral entry into cells to the development of vaccine candidates that elicit virus-neutralizing antibodies.

Biological E. Limited (BE) has embarked on several initiatives for business expansion in recent years, including development of generic injectables with a focus on the regulated markets and exploring synthetic biology and metabolic engineering as a means to manufacture active pharmaceutical ingredients sustainably. In this context, Ms. Mahima Datla, Managing Director of Biological E. Limited said “the recent years have heralded a period of transformation for BE, both in terms of its pipeline of product offerings as well as its geographical footprint. Transitioning from being a generic vaccines manufacturer to a novel vaccines developer is indeed a momentous milestone for the company as it continues to evolve.”

BE has historically developed and manufactured generic vaccines for the emerging markets. To ensure optimal emphasis on the new initiative, the company plans to focus on developing novel vaccines to address unmet medical needs for the global markets.

Mr. Narender Dev Mantena,: Director of BioE Holdings Inc., who is heading this new initiative, said “We are very excited at the prospect of developing the Polyomavirus vaccine candidates from the NCI. These augment our development pipeline of novel vaccines that currently includes a next generation Pneumococcal Conjugate Vaccine (in-house) that covers over 20 serotypes and a Staphylococcus aureus vaccine (partnered).”

About Biological E. Limited

Biological E. Limited (BE), a Hyderabad-based Pharmaceutical Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies generic vaccines and therapeutics. BE supplies its vaccines to over 100 countries while its therapeutic products are sold in India.

In recent years, BE has embarked on new initiatives for organisational expansion such as developing generic injectable products for the regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

BioE Holdings Inc. is a subsidiary of Biological E. Limited.

Media Contact:
K. Vijay Amruth Raj
TEL: +91 8374077433

To read more Press Release articles, click here.